1.
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
2.
3.
4.
5.
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.
6.
7.
8.